Worldwide Anti-infective Agents Market Outlook 2019-2026 - Led by Abbott, Gilead Sciences, Bristol-Myers Squibb, Merck & Co, Bayer, AstraZeneca, Boehringer Ingelheim, and Novartis

Dublin, April 11, 2019 (GLOBE NEWSWIRE) -- The "Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By Distribution Channel, And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.



The global anti-infective agents market size is expected to reach over USD 144.8 billion by 2026 according to this report. It is anticipated to expand at a CAGR of 3.4% during the forecast period.



Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.



Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongst people regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.



However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.



Further key findings from the report suggest:

• Antiviral was estimated to be the largest segment with a market share of 48.8% in 2018 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
• Antibacterial segment is anticipated to register the fastest CAGR of 4% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
• Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
• Oral route of administration was estimated to be the largest segment in 2018 owing to new product development and presence of strong product pipeline
• Hospital pharmacy led the anti-infective agents market in 2018 while e-commerce is expected to be the fastest growing segment during the forecast period
• North America was one of the leading regions in terms of revenue in 2018. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
• Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
• Some of the major companies operating in this market are Abbott; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim; and Novartis AG
• Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Welcome Trust

Companies Mentioned

• GlaxoSmithKline PLC
  
  
• Pfizer Inc.
• Bayer AG
• Sanofi
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• Abbott
• Novartis AG
• Johnson & Johnson Services Inc.
• Astellas Pharma Inc.
• Gilead Sciences Inc.

For more information about this report visit https://www.researchandmarkets.com/r/8dclmt

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs